Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Great Expectations: Sutent, Exubera Forecasts Exceed Those Of Investors

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm projects 2010 annual sales of $2 bil. for the inhaled insulin and $1.5 bil. for the oncologic.

You may also be interested in...



Exubera Launch Falls Back To Early Autumn

Pfizer will roll out an education program for physicians and patients at the end of July and will launch the inhaled insulin in September.

Exubera Launch Falls Back To Early Autumn

Pfizer will roll out an education program for physicians and patients at the end of July and will launch the inhaled insulin in September.

Pfizer Breathes Easy: FDA Approves Exubera

Pfizer's Exubera is the first inhaled insulin to clear FDA; labeling recommends lung function testing.

Related Content

Topics

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel